Adverse events following measles, mumps, and rubella vaccine in adults reported to the vaccine adverse event reporting system (VAERS), 2003-2013

Clinical Infectious Diseases

Volumn 60, Issue 10, 2015, Pages e58-e65

  Sukumaran, Lakshmi ^a,b   McNeil, Michael M ^a   Moro, Pedro L ^a   Lewis, Paige W ^a   Winiecki, Scott K ^c   Shimabukuro, Tom T ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

measles; MMR vaccine; mumps; rubella; Vaccine Adverse Event Reporting System (VAERS)

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ADVERSE OUTCOME; AGED; ANAPHYLAXIS; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; CAUSE OF DEATH; DISEASE DURATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; ENCEPHALITIS; ERYTHEMA; FAINTNESS; FATIGUE; FEMALE; FIRST TRIMESTER PREGNANCY; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HUMAN; HYPESTHESIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MYELITIS; MYOCARDITIS; OLIGOHYDRAMNIOS; PAIN; PREMATURE LABOR; PRIORITY JOURNAL; PRURITUS; SEIZURE; SOLDIER; SPONTANEOUS ABORTION; VACCINATION; VAGINA BLEEDING; VIRUS SHEDDING; YOUNG ADULT; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXANTHEMA; FEVER; INCIDENCE; PATHOLOGY; PREGNANCY; PUBLIC HEALTH SERVICE; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARTHRALGIA; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXANTHEMA; FEMALE; FEVER; HUMANS; INCIDENCE; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MIDDLE AGED; PAIN; PREGNANCY; UNITED STATES; YOUNG ADULT;

EID: 84928968132     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ061     Document Type: Article

References (29)

1. Committee on Infectious Diseases, American Academy of Pediatrics. Recommended childhood and adolescent immunization schedule- United States, 2014. Pediatrics 2014; 133:357-63.
2. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2013. Ann Intern Med 2013; 158:191-9.
3. McLean HQ, Fiebelkorn AP, Temte JL,Wallace GS; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-04):1-34.
4. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1-8.
5. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292:351-7.
6. France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121:e687-92.
7. Centers for Disease Control and Prevention. Nationwide campaign for vaccination of adults against rubella and measles-Costa Rica, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:976-9.
8. Chen RT, Moses JM, Markowitz LE, OrensteinWA. Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine 1991; 9:297-9.
9. Yalcin SS, Kanra G, Pehlivan T. Outbreak of measles in medical students and determination of immune status to measles-mumps-rubella viruses. Int J Adolesc Med Health 2006; 18:615-22.
10. Gastanaduy PA, Redd SB, Fiebelkorn AP, et al. Measles-United States, January 1-May 23, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:496-9.
11. Delaporte E, Wyler Lazarevic CA, Iten A, Sudre P. Large measles outbreak in Geneva, Switzerland, January to August 2011: descriptive epidemiology and demonstration of quarantine effectiveness. Euro Surveill 2013; 18:pii:20395.
12. European Centre for Disease Prevention and Control. Surveillance report: measles and rubella monitoring, October 2013. Available at: http://www.ecdc.europa.eu/en/publications/Publications/measlesrubella-surveillance-oct-2013.pdf. Accessed 7 October 2014.
13. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23:287-94.
14. US Department of Health and Human Services. Vaccine Adverse Event Reporting System (VAERS) form. Available at: https://vaers.hhs.gov/esub/step1. Accessed 4 February 2014.
15. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical dictionary for regulatory activities (MedDRA). Available at: http://www.meddra.org/. Accessed 4 February 2014.
16. Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010; 28:7248-55.
17. Ruggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5675-84.
18. Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5771-92.
19. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:599-612.
20. Wise RP, Bonhoeffer J, Beeler J, et al. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5717-24.
21. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2011; 205:473 e1-9.
22. Cunningham FG,Williams JW.Williams obstetrics. 23rd ed. New York: McGraw-Hill Medical, 2010.
23. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999; 53:177-90.
24. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the USFDA's spontaneous reports database. Drug Saf 2002; 25:381-92.
25. Martin D, Menschik D, Bryant-Genevier M, Ball R. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. Drug Saf 2013; 36: 547-56.
26. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979; 110: 105-23.
27. Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997; 100:767-71.
28. SAGE Working Group on Measles and Rubella. Status report on progress towards measles and rubella elimination. Available at: http://www.who.int/immunization/sage/meetings/2013/november/Status-Report-Measles-Rubella21Oct2013-FINAL.pdf. Accessed 4 February 2014.
29. Centers for Disease Control and Prevention. Measles Cases and Outbreaks. Available at: http://www.cdc.gov/measles/cases-outbreaks.html. Accessed 10 February 2015.